1460778899-c28badd0-a43f-4866-bc53-fca5cdf9f1be

1. A liquid crystal display device comprising:
a first substrate provided with a first electrode;
a second substrate provided with at least one second electrode, which is arranged opposite to the first electrode with a predetermined gap therebetween, and which forms an individual pixel region in which the second electrode faces the first electrode;
an auxiliary electrode formed on a surface of the second substrate on which the second electrode is provided, along at least a periphery of the pixel region;
a vertical alignment film formed on each of opposing inner surfaces of the first electrode and the second electrode;
a liquid crystal layer with a negative dielectric anisotropy filled between the first and second substrates;
an aperture, formed in at least one of the first electrode and the second electrode for the pixel region, for segmenting the pixel region into a plurality of sub-pixel regions; and
a transparent step film comprising a transparent member which overlaps the auxiliary electrode on the surface of the second substrate on which the second electrode is provided, along at least the periphery of the pixel region, wherein the transparent step film forms an inclined surface which protrudes from the surface on which the second electrode is formed, and wherein the inclined surface is formed at the periphery of the pixel region on the surface on which the second electrode is provided such that liquid crystal molecules of the liquid crystal layer are aligned to tilt toward an inner side of the pixel region.
2. The liquid crystal display device according to claim 1, wherein the aperture is formed in the second electrode, and the auxiliary electrode comprises an aperture auxiliary electrode laid out at a portion corresponding to the aperture of the second electrode, and
wherein the auxiliary electrode surrounds each of the plurality of sub-pixel regions segmented by the aperture.
3. The liquid crystal display device according to claim 2, wherein the aperture auxiliary electrode is formed by a transparent conductive film.
4. The liquid crystal display device according to claim 1, wherein the aperture is formed in the second electrode, and the transparent step film comprises an aperture step film positioned so as to correspond to the aperture of the second electrode and so as to overlap the auxiliary electrode.
5. A liquid crystal display device comprising:
a first substrate provided with a first electrode;
a second substrate provided with at least one second electrode, which is arranged opposite to the first electrode with a predetermined gap therebetween, and which forms an individual pixel region in which the second electrode faces the first electrode;
a first auxiliary electrode formed on a surface of the second substrate on which the second electrode is provided, along at least a periphery of the pixel region;
a vertical alignment film formed on each of opposing inner surfaces of the first electrode and the second electrode;
a liquid crystal layer with a negative dielectric anisotropy filled between the first and second substrates;
a slit, formed in the second electrode, for segmenting the pixel region into a plurality of sub-pixel regions so that molecular long axes of liquid crystal molecules of the liquid crystal layer are aligned toward a center of each of the plurality of sub-pixel regions from a circumference thereof by an electric field generated in the slit;
a second auxiliary electrode, which is insulated from the second electrode, and which is formed on the surface of the second substrate on which the second electrode is provided, at a position corresponding to the slit;
a first transparent step film comprising a transparent member which overlaps the first auxiliary electrode on the surface of the second substrate on which the second electrode is provided, along at least the periphery of the pixel region, wherein the first transparent step film forms a first inclined surface which protrudes from the surface on which the second electrode is formed, and wherein the first inclined surface is formed at the periphery of the pixel region on the surface on which the second electrode is provided such that the liquid crystal molecules of the liquid crystal layer are aligned to tilt toward inner sides of the sub-pixel regions; and
a second transparent step film comprising a transparent member which overlaps the second auxiliary electrode on the surface of the second substrate on which the second electrode is provided, wherein the second transparent step film forms a second inclined surface which protrudes from the surface on which the second electrode is formed, and wherein the second inclined surface is formed at peripheries of the sub-pixel regions on the surface on which the second electrode is provided such that the liquid crystal molecules of the liquid crystal layer are aligned to tilt toward the inner sides of the sub-pixel regions.
6. The liquid crystal display device according to claim 5, wherein the slit comprises a plurality of cutaway portions which extend toward the periphery of the pixel region from a center portion thereof, and which are connected to one another at the center portion of the pixel region.
7. The liquid crystal display device according to claim 5, wherein the first auxiliary electrode is set to a potential that is lower than a potential of the second electrode.
8. The liquid crystal display device according to claim 5, wherein the first auxiliary electrode is set to a potential that is equal to a potential of the first electrode facing the second electrode.
9. The liquid crystal display device according to claim 5, wherein the first auxiliary electrode comprises a compensating-capacitor electrode which overlies a peripheral portion of the second electrode and forms a compensating capacitor between the compensating-capacitor electrode and the second electrode.
10. The liquid crystal display device according to claim 5, wherein the second auxiliary electrode is connected to the first auxiliary electrode.
11. The liquid crystal display device according to claim 5, wherein the second auxiliary electrode comprises a transparent conductive film.
12. The liquid crystal display device according to claim 5, wherein each of the first and second transparent step films has a scatter reflection film formed on a top surface thereof.
13. The liquid crystal display device according to claim 5, wherein a recess and protrusion portion are formed on a top surface of each of the first and second transparent step films, and a metal film which scatters and reflects light is formed on the recess and protrusion portion.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof or a mixture of stereoisomers,
wherein:
R1 is a radical selected from the group consisting of: phenyl, and phenyl mono-, di-, or tri-substituted by a radical independently selected from the group consisting of F, Cl, Br, I, (C1-C6)-alkyl, COO-(C1-C6)-alkyl, and (C1-C6)-alkoxy; and
R2 is a radical selected from the same group as R1, further including, a phenyl substituted in 4-position by a radical independently selected from the group consisting of \u2014O(CH2)CONH(CH2)3CH3 and \u2014OCH2COOC(CH3)3, a biphenyl-4-yl, a thiazol-2-yl, and a thiazol-2-yl mono- or di-substituted, in 4 or 5 positions, by a radical selected from the group consisting of F and phenyl.
2. The compound of formula (I) as defined in claim 1, wherein: R2 is a radical selected from the same group as R1, further including a biphenyl-4-yl, a thiazol-2-yl, and a thiazol-2-yl mono- or di-substituted, in 4 or 5 positions, by a radical selected from the group consisting of F and phenyl.
3. The compound according to claim 2, wherein R1 is selected from the group consisting of: phenyl, and phenyl mono-substituted by a radical independently selected from the group consisting of Cl, (C1-C4)-alkyl, and \u2014COO-(C1-C4)-alkyl.
4. The compound according to claim 3, wherein R1 is selected from the group consisting of: phenyl, 4-ethylphenyl, 4-chlorophenyl, 2-methylphenyl, 4-methylphenyl, 2-ethoxyphenylcarbonyl, and 4-ethoxyphenylcarbonyl.
5. The compound according to claim 2, wherein R2 is a radical selected from the group consisting of: phenyl, and phenyl mono-substituted by a radical independently selected from the group consisting of Cl, (C1-C4)-alkyl, and COO-(C1-C4)-alkyl.
6. The compound according to claim 5, wherein R2 is a radical selected from the group consisting of: phenyl, 4-ethylphenyl, 4-chlorophenyl, 2-methylphenyl, 4-methylphenyl, and 2-ethoxyphenylcarbonyl, and 4-ethoxyphenylcarbonyl.
7. The compound according to claim 2, wherein R2 is biphenyl-4-yl.
8. The compound according to claim 2, wherein R2 is 5-phenylthiazol-2-yl or 4-fluoro-5-phenylthiazol-2-yl.
9. The compound according to claim 1, wherein R2 is phenyl substituted in 4 position by \u2014O(CH2)CONH(CH2)3CH3 or by OCH2COOC(CH3)3.
10. The compound according to claim 2, which is selected from the following table:
Compound
(I)
R1
R2
Ia
Phenyl
4-fluoro-5-phenylthiazol-2-yl
Ib
Phenyl
5-phenylthiazol-2-yl
Ic
Phenyl
phenyl
Id
4-chlorophenyl
4-chlorophenyl
Ie
Phenyl
biphenyl-4-yl
If
4-methylphenyl
4-ethoxycarbonylphenyl
11. (canceled)
12. A method of treatment of a mammal suffering from or being susceptible of suffering from cancer, the method comprising administering to the mammal a therapeutically effective amount of compound of formula (I), as defined in claim 1, together with pharmaceutically acceptable excipients or carriers.
13. A method of treatment according to claim 12, wherein the cancer is selected from the group consisting of leukemia, lymphoma, cervical carcinoma, breast adenocarcinoma, glioblastoma, and hepatocellular carcinoma.
14. A method of treatment according to claim 13, wherein the cancer is leukemia or lymphoma.
15. A method of treatment according to claim 14, wherein the leukemia or lymphoma are B-cell neoplasms.
16. A pharmaceutical composition comprising a therapeutically effective amount of the compound as defined in claim 1, together with adequate amounts of pharmaceutical excipients or carriers.
17. A preparation process of a compound of formula (I) as defined in claim 1, comprising:
a) first submitting a compound of formula (II), wherein X is an halogen,
to a Suzuki coupling with a compound of formula R1B(OH)2, wherein R1 has the same meaning as for compound (I), in the presence of a palladium catalyst, followed by submitting the compound obtained to a fluorination reaction with a fluorinating agent, to give a compound of formula (I) with R1\u2550R2; or, alternatively,
b) first submitting a compound of formula (III)
to a Suzuki coupling with a compound of formula R2B(OH)2 wherein R2 is a radical selected from the same group as R1, further including biphenyl-4-yl, and R1 having the same meaning as for compound (I), in the presence of a palladium catalyst, then halogenating the compound obtained with a halogen source, subsequently coupling the compound obtained with a compound of formula R1B(OH)2 wherein R1 has the same meaning as for compound (I), in the presence of a palladium catalyst, and finally submitting the compound obtained to a fluorination reaction with a fluorinating agent to give a compound of formula (I) with R1 different from R2; or alternatively,
c) first submitting a compound of formula (III) to a Suzuki coupling with a compound of formula R2B(OH)2 wherein R2 is a radical selected from the same group as R1, further including biphenyl-4-yl, and R1 having the same meaning as for compound (I), in the presence of a palladium catalyst, then submitting the compound obtained to a C\u2014H activation reaction with a compound of formula R1I wherein R1 has the same meaning as for compound (I); and then submitting the compound obtained to a fluorination reaction with a fluorinating agent to give a compound of formula (I) with R1 different from R2; or alternatively,
d) submitting a compound of formula (III) to a homocoupling reaction in the presence of a palladium catalyst, then halogenating the compound obtained with a halogen source, followed by submitting the compound obtained to a Suzuki coupling with a compound of formula R1B(OH)2, wherein R1 has the same meaning as for compound (I), in the presence of a palladium catalyst, and, finally, by submitting the compound obtained to a fluorination reaction with a fluorinating agent to give a compound of formula (I) where R1 is phenyl and R2 a thiazol-2-yl substituted by a phenyl; and
e) optionally, converting the compounds obtained in any of the processes a) to d) into a pharmaceutically acceptable salt by reaction of the compound (I) with a pharmaceutically acceptable acid or a pharmaceutically acceptable base to yield the corresponding pharmaceutically acceptable salt.